The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
Lenire is the first and only bimodal neuromodulation device to be awarded a Federal Supply Schedule (FSS) Contract from the US Government
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Subscribe To Our Newsletter & Stay Updated
